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Abstract: Pulmonary embolism (PE) represents a common disease in emergency medicine 
and guidelines for diagnosis and treatment have had wide diffusion. However, PE morbidity 
and mortality remain high, especially when associated to hemodynamic instability or right 
ventricular dysfunction. Prognostic stratification to identify high risk patients needing to receive 
more aggressive pharmacological and closer monitoring is of utmost importance. Modern 
guidelines for management of acute PE are based on risk stratification using either clinical, 
radiological, or laboratory findings. This article reviews the modern treatment of acute PE, which 
is customized upon patient prognosis. Accordingly the current risk stratification tools described 
in the literature such as clinical scores, echocardiography, helical computer tomography, and 
biomarkers will be reviewed.
Keywords: pulmonary embolism, prognosis, troponin, BNP, NT-proBNP, echocardiography, 
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Introduction
Pulmonary embolism (PE) remains one of the leading causes of morbidity and 
mortality in the emergency and cardiovascular setting, especially when associated to 
hemodynamic instability. In the United States, about 150.000 patients per year are 
diagnosed with acute PE, resulting in thousands of recognized deaths annually from 
massive PE. Mortality for PE is 2% in normotensive patients without evidence of right 
ventricular dysfunction (RVD), but rises up to 30% in patients with shock and up to 
65% in patients with cardiac arrest at presentation.1
Guidelines on diagnosis have had wide diffusion in the last years with strate-
gies based on pre-test clinical probability, D-Dimers levels, ultrasonography of the 
legs, lung scan, and more recently computer tomography pulmonary angiography 
(CTPA).2–9 Concomitantly modern concepts about mortality risk evaluation, prognostic 
stratification and consequent treatment have also emerged. Therefore the aim of the 
present literature review is to summarize the concept of PE risk stratification focusing 
on emerging stratification tools and discuss its consequences in clinical practice.
Pathophysiology, clinical classification, and modern 
concepts of treatment of acute PE
The pathophysiological response to acute PE is of utmost importance to understand 
its hemodynamic consequences, which in turn will affect patient prognosis. Patient 
prognosis depends on the extent to which pulmonary artery blood flow is obstructed, Vascular Health and Risk Management 2009:5 568
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pre-existing cardiopulmonary disease, and the release of 
vasoactive humoral factors from clots.1,6 The mechanical 
obstruction formed by the clot, together with the pulmonary 
artery vasoconstriction stimulated by neurohumoral 
substances (such as serotonin from platelets, thrombin from 
plasma, and histamine from tissue) and hypoxemia, could 
cause increased pulmonary vascular resistance and right 
side cardiac afterload, which in turn can result in cardiac 
dilatation, hypokinesis, and myocardial ischemia. In some 
patients, a rapid progression in systemic arterial hypotension 
and cardiogenic shock may occur. Cardiac arrest and death 
could be the fatal evolution.1,6,10 This cascade could explain 
some important consequences in biomarkers increase; 
myocardial damage represented by micro-infarcts leads to 
increased levels of cardiac troponins (cTn) and heart type 
fatty acid-binding proteins (H-FABP), whereas wall stress 
caused by higher right heart after-load leads to increased 
levels of natriuretic peptides (NP). Figure 1 summarizes the 
hemodynamic consequences of PE.
Classically PE has been subdivided in massive, hemo-
dynamically unstable (hypotension is defined as arterial 
blood pressure less than 90 mmHg, shock, or cardiac arrest), 
submassive (normotensive PE with evidence of RVD) or 
nonmassive (normotensive PE without RVD), which are both 
hemodynamically stable.2–5 About 5% of acute PE are repre-
sented by massive PE. About 50% of normotensive patients 
have trans-thoracic echocardiographic (TTE) pattern of RVD, 
and around 10% will die.11
The European Society of Cardiology (ESC) recommends 
classifying PE according to classes of risk for adverse prognosis.12 
Therefore PE is divided into high risk (corresponding to massive 
PE with short term mortality 15%) and nonhigh risk. Nonhigh 
risk patients are normotensive. The presence of increased NP and/
or troponins is currently not mandatory for defining the high risk 
class. As many normotensive patients often present with RVD 
and potential adverse outcomes, nonhigh risk PE has been further 
divided into intermediate risk (corresponding to submassive PE: 
normotensive plus signs of RVD and/or signs of myocardial 
damage, short-term mortality being 3%–15%) and in low risk 
(corresponding to nonmassive PE: normotensive without signs 
of RVD and myocardial damage, short-term mortality  3%).12 
Figure 2 shows ESC criteria for risk assessment.
Acute treatment of  PE is customized by mortality risk based 
upon prognostic stratification. In their new guidelines, the ESC 
and American College of Chest Physicians (ACCP) suggest 
treatment of PE according to clinical risk.12,13 In massive-high risk 
PE, thrombolysis with alteplase (rtPA), streptokinase, or uroki-
nase is the recommended therapy. Embolectomy could represent 
an alternative therapy for patients with shock in the acute setting 
when thrombolysis is contraindicated or when it has been 
unsuccessful. In submassive-intermediate risk PE, thrombolysis 
has been proposed in selected patients at high risk for adverse 
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Figure 1 Pathophysiology of hemodynamic instability due to PE and mechanism of biomarkers increase.
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prognosis without contraindications (grade IIB of ESC and 
ACCP VIII Edition),13 whereas intravenous unfractioned heparin 
(UFH) should be reserved to conditions in which thrombolysis 
is contraindicated (grade IA ESC and ACCP VIII Edition). In 
nonmassive-low risk PE, subcutaneous low-molecular weight 
heparins (LMWH) or fondaparinux are recommended (grade 
IA ESC and ACCP VIII Edition). As this subgroup of patients 
represent the majority of PE patients and that ambulatory 
treatment has been reported to be safe, early identification of 
such patients at admission could potentially lead to a substantial 
decrease in hospitalization rates and PE-related costs.14,15 Vitamin 
K antagonists (VKA) should be started in the first day and should 
be overlapped with UFH and LMWH or fondaparinux for at least 
five days (grade I A ESC and ACCP VIII Edition).12,13
Figure 3 summarizes the choice treatment in different 
class of risk for patients with acute PE. Thus, PE risk stratifi-
cation will become fundamental not only to select appropriate 
treatment strategy, but also to potentially reduce the costs of 
PE management. For both purposes, several risk stratification 
algorithms have been reported in the literature, including 
clinical, radiological, and laboratory parameters.
Risk evaluation and prognostic 
stratification
Clinical parameters and clinical scores
Shock or systemic blood hypotension at presentation represent 
the most important clinical sign of poor prognosis in patients 
with acute PE.1,11 In the ICOPER Study, the mortality rate was 
58.3% in patients who were hemodynamically unstable at the 
time of presentation and 15.1% for those who were hemody-
namically stable.11 Other clinical variables, easily available 
at admission, associated to poor prognosis are represented by 
age over 70 years, history of bed rest over five days, cancer, 
chronic obstructive pulmonary disease, renal failure, heart 
failure, cardiovascular diseases, and tachycardia.10
The Pulmonary Embolism Prognostic Index (PESI), 
and Geneva Prediction Rule represent two clinical scores 
identifying classes of patients with increased risk of adverse 
outcomes.16,17 These scores reliably identify low-risk patients 
with PE (patients classified as PESI classes I and II) who 
could be candidates for less costly ambulatory treatment. The 
major strength of these score is their easy use in all clinical 
setting; the disadvantage is that they have not been compared 
to more recent prognostic factors (such as biomarkers and 
imaging findings). In fact, PESI seems to be more accurate 
for predicting low risk patients than the Geneva Prediction 
Rule.18 The PESI score tool is displayed in Figure 4.
The shock index, heart rate (beats for minute)/systolic 
blood pressure (mmHg) ratio, is a simple method to predict 
high risk patients for adverse outcome, when its value is over 
1. This ratio has been shown to be related to in-hospital mor-
tality and it is sensitive to predict poor prognosis alone or in 
combination with trans-thoracic echocardiogram (TTE).19,20 
12-lead ECG findings of poor prognosis are represented by 
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Figure 2 ESC criteria for identifing the risk of adverse prognosis in acute PE.
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presence and number of T waves inversion in precordial 
leads and QR in V1,21–23 but overall, ECG does not seem to 
be a reliable marker of severity of PE.
echocardiographic and radiological 
parameters
TTE represents the most useful tool in everyday clinical 
practice to show RVD because of its noninvasive nature and 
relative low cost. Hence, RVD assessed on TTE has been 
described as one of the strongest predictor of early mortality 
in nonmassive PE.24–26
The main TTE findings detectable in PE are represented 
by right ventricle hypokinesis (mild, moderate, severe), right 
ventricle dilatation (especially represented by four chambers 
end-diastolic RV/left ventricular [LV] ratio  1), and signs 
of pulmonary hypertension. The presence of RVD is related 
to poor prognosis in PE with hemodynamic instability.11,25 
Furthermore, TTE detects RVD in about 30%–40% of 
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Figure 4 Pulmonary embolism severity index (P.E.S.I). Modified from Aujesky D, Perrier A, Roy PM, et al. Validation of a clinical prognostic model to identify low-risk patients with 
pulmonary embolism. J Intern Med. 2007;261:597–604.
Abbreviations: COPD, chronic obstructive pulmonary disease; HR, heart rate; bpm, beats per minute; SBP, systolic blood pressure; RR, respiratory rate; BT, body temperature; 
SaO2, arterial saturation of oxygen.
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Figure 3 Pe treatment according to modern guidelines.
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normotensive patients (systolic blood pressure  90 mmHg) 
at presentation.24,25 Thirty-day mortality of normotensive 
patients with RVD is two-fold compared to normotensive 
patients without RVD.27 RVD at presentation seems also to 
predict poor pulmonary clot resolution six months after the 
initial event and a higher incidence of VTE recurrence.28 
Fremont and colleagues reported data from a monocentric 
study enrolling more than 1400 patients. The authors found 
that an TTE RV/LV diameter ratio  0.9 was an independent 
risk factor for hospital mortality in normotensive patients with 
PE.29 A recent review has shown that in-hospital mortality of 
normotensive patients without RVD was 0%–9.6% compared 
to 11.8%–23% for patients with RVD.30 However other studies 
which evaluated the prognostic value of TTE in normotensive 
PE patients were less convincing.31,32 The limit of TTE exami-
nation is that the test is operator-dependent and not necessarily 
available around the clock in all institutions. Moreover TTE 
criteria of RVD are not definitely established.
Currently, CTPA represents the diagnostic gold standard 
for PE, and is widely integrated in validated diagnostic strate-
gies.6–8,33 Recently several studies focused on the correlation 
between findings of CTPA, presence of RVD, and prog-
nosis of PE.34–42 The Computer Tomography Pulmonary 
Embolism (CTPE) index combines distribution and severity 
of vascular obstruction of clots in pulmonary circulation; PE 
severity seems to be linearly related to CTPE index values.40 
Ghanima and colleagues have proposed to divide the pulmo-
nary vascular tree in four groups of arteries: sub-segmental, 
segmental, lobar, and main pulmonary artery with its (left 
and right) branches (respectively named 1, 2, 3, 4).41 These 
authors showed that the pulmonary artery obstruction index 
was correlated to troponin T levels, CTPA RV/LV diameter 
ratio and partial pressure of  oxygen in arterial blood (PaO2).41 
It seems that the Ghanima index could be related also to TTE 
RVD.43 A RV/LV diameter ratio is also easily determined by 
CTPA and the thirty-day mortality rate is 15.6% in patients 
with CTPA RV/LV  0.9 compared to 7.7% in patients 
without RV enlargement.42 However these results have not 
been confirmed in the PIOPED II trial.44 Finally, CTPA seems 
to be a promising method for PE prognosis stratification, but 
the sample size of these previous studies precludes any firm 
conclusion. Thus, further studies are warranted to assess 
CTPA as a prognostic tool, because it could be very useful 
for clinicians to have at the same time a validated diagnostic 
tool, with an additional prognostic value.
Pulmonary real-time magnetic resonance (rtMR) and 
magnetic resonance angiography (MRA) represent a safe 
alternative and/or complementary examination compared 
with CTPA both as diagnostic imaging and for detecting RV 
enlargement or dysfunction.45–49
Laboratory parameters
Arterial blood gas analysis (BGA) remains a first-line exami-
nation in patients with suspected PE for evaluation of gas 
exchange and acid-base status. The role of BGA as prognostica-
tor has been studied with discordant results between younger 
and elderly patients. Much recently hypoxemia was found as 
an independent negative predictor of three-month all-cause 
mortality in PE patients (hazard ratio [HR] 5.7, 95% confidence 
interval [CI]: 2.1–15.1).50 PaO2 values have been demonstrated 
to be linearly associated to CTPA parameters such as proximal 
extension of pulmonary clots and RV/LV diameter.41 Parameters 
derived from BGA, such as alveolar-arterial oxygen gradient 
(values  50 mmHg) and arterial–alveolar oxygen tension ratio 
(values  0.50) have been demonstrated to be associated to poor 
prognosis in nonelderly patients with PE.51,52 Moreover, alveolar 
dead space measured from volumetric capnography and BGA 
seems to correlate with embolic burden of PE.53 In elderly PE 
patients, only lower arterial oxygen saturation seems to predict 
short-term mortality; neither PaO2 nor alveolar–arterial oxygen 
gradient seem to identify high risk patients.54
D-Dimer values seems to be linearly related to the 
extend of the clot and the severity of PE.43,55–57 One study 
demonstrated that patients who had D-Dimer levels below 
1500 µg/L have a very low mortality.56
As detailed below, cardiac biomarkers, such as cardiac 
troponins, (cTnI and cTnT), NP, H-FABP, myoglobin, 
and growth differentiation factor-15 have been extensively 
evaluated as risk stratification tools in PE.
Troponins are released in the bloodstream in presence 
of myocardial damage secondary to microinfarction.58 
The increase of troponins is correlated with TTE RVD 
and CTPA findings and its elevation has a strong negative 
prognostic value.59 Many studies have demonstrated the 
negative prognostic values of increased troponins in PE.60–64 
Becattini and colleagues have published a meta-analysis 
on the relation between troponins and mortality and 
morbidity in acute PE.65 They confirmed that the increase of 
troponins I and/or T was associated with a higher mortality 
(17.9% in patients with elevated troponin levels and 
2.3%in patients with normal troponin levels), even in the 
subgroup of hemodynamically stable patients (odds ratio, 
4.12).65,66 Jimenez and colleagues also confirmed in a large 
prospective study that elevated cTnI predicted fatal PE in 
hemodynamically stable patients; the negative predictive 
value of a negative cTnI for mortality was 93%.67Vascular Health and Risk Management 2009:5 572
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NP secretion is due to RV wall strech and therefore due to 
RVD.68 The increase of the B (B type) NP biomarker (BNP 
and its amino terminal portion, NT-proBNP) is highly sensi-
tive but poorly specific for detecting RVD and patients at risk 
of severe adverse events such as cardiac arrest, shock, need 
for thrombolysis or vasopressors or mechanical ventilation, 
or need for intensive care units.69–83 Two studies suggested 
that NT-proBNP correlated better with prognosis when 
compared to troponins,84,85 especially in combination with 
TTE.84 Several recent reviews and meta-analyses strongly 
confirmed the prognostic usefulness of NP.86–89
H-FABP, a small cytosolic protein released earlier 
than troponins into circulation when the myocardium is 
injured, has been evaluated as a prognostic tool and small 
studies suggested that this cardiac biomarker could also 
identify the patients with poorer outcomes when compared 
to cTns and BNP/NT-proBNP.90,91 The negative prognostic 
role of myoglobin and growth-differentiation factor-15 
(gdf-15), a cytokine induced in the heart after ischemia or 
pressure overload, in acute PE have also been reported.92,93 
However, H-FABP and gdf-15 measurements are not yet 
widely available.
Figure 5 summarizes the results of studies which evalu-
ated various clinical, instrumental, and laboratory indexes for 
predicting poor outcomes in acute PE. This figure suggests 
that cardiac biomarkers have all been shown to correlate with 
RV dysfunction/dilatation and prognosis in PE.
However, because most of those studies did not perform 
an extensive comparison between all the available biomarkers, 
knowing which one will yield the best prognostic value still 
remains debated. Among other limitations worth to be men-
tioned are that different biomarkers thresholds were used (and 
often determined retrospectively), and that various outcome 
definitions were used in the aforementioned studies. In order 
to compare their respective prognostic value, it will be nec-
essary to use uniform pre-defined cut-offs. One possibility 
would be to use the cut-offs validated in their respective initial 
context. To this respect, a small systematic prospective com-
parative study using the pre-defined and validated thresholds 
(either in acute coronary syndrome or heart failure) for NT-
proBNP, BNP, H-FABP, and myoglobin showed that only 
NPs (BNP or NT-proBNP) were significantly correlated with 
RV dilatation on CTPA.94 Those results are corroborated by a 
recent multicentre study showing that NT-proBNP appeared 
as the most effective biomarker for rule-out purposes in non-
massive PE.95 Using the commonly defined cut-off of 300 
pg/ml validated for heart failure,96 this test had a negative 
predictive value of 100% (95% CI: 91–100).95
Defining which of those biomarkers should be used as 
rule-out or rule-in test needs further clarification, but based 
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Figure 5 Clinical, instrumental and laboratory parameters associated with adverse outcomes in patients with acute Pe.
Abbreviations: SBP, systolic blood pressure; ECG, echocardiogram; ESI, Pulmonary Embolism Severity Index; RVD, right ventricular dysfunction; CTPA, computer tomography 
pulmonary angiography; BNP, brain natriuretic peptides; HTFABP, heart type fatty acid binding protein; GFD-15, Growth differentiation factor-15; CTPE, computer tomography 
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upon the aforementioned observations, it appears that BNP/
NT-proBNP and cTnI could potentially be used as rule-out 
tests. Finally, determining whether a biomarker alone or 
in combination with other clinical or radiological or ECG 
features would add incremental prognostic value deserves 
further study. Overall, NP (BNP or NT-proBNP) and cTns, 
with their 24-hour availability in most of emergency labora-
tories, could represent very convenient prognostic tools for 
PE risk stratification in an acute setting, especially in the 
institutions where echocardiography is not widely available.
Concerning the identification of patients, two major 
points are under investigation. First, it becomes of utmost 
importance to select patients who may be safely treated on 
an outpatient basis, and both clinical scores97 or probably 
biomarkers like NT-pro-BNP95 may fulfil this request. This 
hypothesis is being currently tested in a prospective study (the 
OTPE trial).98 Second, there is a need to better define which 
patient may benefit from fibrinolysis, and at least one random-
ized study is comparing anticoagulation against fibrinolysis 
in patients with no hemodynamic failure and RVD on TTE.99 
These currently ongoing studies should allow improvements 
in the care of PE patients in the near future.
Conclusions
Risk evaluation and prognostic stratification are the cornerstones 
of modern acute PE management. The use of either clinical, 
ECG, or biochemical parameters will probably be crucial to 
appropriately select stable patients for fibrinolyis, which currently 
represents one of the utmost therapeutic challenges of PE. For 
the time being, the remaining questions are: 1) which treatment 
should be reserved to submassive PE patients? 2) What is the 
best modality to identify such patients: TTE, CTPA, biomarkers, 
or clinical scores? 3) Could a combination of such stratification 
tools add incremental value to one modality alone?
Intend-to-treat and noninferiority trials are now requested 
to resolve those matters. In this respect, the results of 
ongoing randomized multicenter trials, such as the European 
Pulmonary Embolism Thrombolysis (PEITHO) trial,99 are 
eagerly awaited.
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